The role of cetuximab in the treatment of patients with squamous cell carcinoma of the head and neck: resolution of the Expert Council

1. Russian Society of Head and Neck Tumors Specialists, Association of Russian Oncologists. Larynx cancer. Clinical guidelines. Available at: http://oncology-association.ru/files/clinical-guidelines_adults/rak_gortani.pdf (In Russ.).

2. Bonner J.A., Harari P.M., Giralt J. et al. Radiotherapy plus cetuximab for squamous cell carcinoma of the head and neck. N Engl J Med 2006;354(6):567—78. DOI: 10.1056/NEJMoa053422. PMID: 16467544.

3. Bonner J.A., Mesia R., Giralt J. et al. p16, HPV, and cetuximab: what is the evidence? Oncologist 2017;22(7):811 —22. DOI: 10.1634/theoncologist.2016-0433. PMID: 28526718.

4. Vermorken J.B., Mesia R., Rivera F. et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359(11): 1116-27. DOI: 10.1056/NEJMoa0802656. PMID: 18784101.

5. Burtness B., Harrington K.J., Greil R. et al. KEYNOTE-048: phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). Available at: https://www.esmo.org/Press-Office/Press-Releases/KEYNOTE048-head-neck-cancer-immunotherapy-Burtness.

6. Saleh K., Daste A., Martin N. et al. Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with squamous cell carcinoma of the head and neck. J Clin Oncol 2018;36(15 suppl). DOI: 10.1200/JCO.2018.36.15_suppl.6015. Available at: http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.6015